^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
BN-Brachyury
i
Other names: BN-Brachyury, MVA-BN brachyury TRICOM vaccine, brachyury/TRICOM, MVA-brachyury-TRICOM, MVA-BN-Brachyury/ FPV-Brachyury, MVA-brachyury-TRICOM vaccine
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Bavarian Nordic
Drug class:
Immunostimulant
Related drugs:
3years
BN-Brachyury, Entinostat, Adotrastuzumab Emtansine and M7824 in Advanced Stage Breast Cancer (BrEAsT) (clinicaltrials.gov)
P1b, N=1, Completed, National Cancer Institute (NCI) | Suspended --> Completed | N=65 --> 1 | Trial completion date: Jan 2024 --> Oct 2021 | Trial primary completion date: Jan 2024 --> Oct 2021
Trial completion • Enrollment change • Trial completion date • Trial primary completion date
|
HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • ER (Estrogen receptor) • PGR (Progesterone receptor) • CD4 (CD4 Molecule)
|
HER-2 positive • HR negative
|
Kadcyla (ado-trastuzumab emtansine) • Jingzhuda (entinostat) • bintrafusp alfa (M7824) • BN-Brachyury
3years
BN-Brachyury, Entinostat, Adotrastuzumab Emtansine and M7824 in Advanced Stage Breast Cancer (BrEAsT) (clinicaltrials.gov)
P1b, N=65, Suspended, National Cancer Institute (NCI) | Recruiting --> Suspended
Trial suspension
|
HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • ER (Estrogen receptor) • PGR (Progesterone receptor) • CD4 (CD4 Molecule)
|
HER-2 positive • HR negative
|
Kadcyla (ado-trastuzumab emtansine) • Jingzhuda (entinostat) • bintrafusp alfa (M7824) • BN-Brachyury
3years
Phase 1 open-label trial of intravenous administration of MVA-BN-brachyury-TRICOM vaccine in patients with advanced cancer. (PubMed, J Immunother Cancer)
Intravenous administration of MVA-BN-brachyury-TRICOM vaccine was safe and tolerable. Maximum tolerated dose was not reached. The maximum administered dose was 10 infectious units every 3 weeks for three doses. This dose was selected as the recommended phase 2 dose.
Clinical • P1 data • Journal
|
CD8 (cluster of differentiation 8)
|
BN-Brachyury • MVA-BN-Brachyury IV vaccine
almost4years
BN-Brachyury, Entinostat, Adotrastuzumab Emtansine and M7824 in Advanced Stage Breast Cancer (BrEAsT) (clinicaltrials.gov)
P1b, N=65, Recruiting, National Cancer Institute (NCI) | Trial completion date: Jan 2022 --> Jan 2024 | Trial primary completion date: Jan 2022 --> Jan 2024
Trial completion date • Trial primary completion date
|
HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • ER (Estrogen receptor) • PGR (Progesterone receptor) • CD4 (CD4 Molecule)
|
HER-2 positive • HR negative
|
Kadcyla (ado-trastuzumab emtansine) • Jingzhuda (entinostat) • bintrafusp alfa (M7824) • BN-Brachyury
almost4years
BN-Brachyury, Entinostat, Adotrastuzumab Emtansine and M7824 in Advanced Stage Breast Cancer (BrEAsT) (clinicaltrials.gov)
P1b, N=65, Recruiting, National Cancer Institute (NCI) | Not yet recruiting --> Recruiting
Enrollment open
|
HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • ER (Estrogen receptor) • PGR (Progesterone receptor) • CD4 (CD4 Molecule)
|
HER-2 positive • HR negative
|
Kadcyla (ado-trastuzumab emtansine) • Jingzhuda (entinostat) • bintrafusp alfa (M7824) • BN-Brachyury
over4years
BN-Brachyury, Entinostat, Adotrastuzumab Emtansine and M7824 in Advanced Stage Breast Cancer (BrEAsT) (clinicaltrials.gov)
P1b, N=55, Not yet recruiting, National Cancer Institute (NCI)
New P1 trial
|
HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • ER (Estrogen receptor) • PGR (Progesterone receptor) • CD4 (CD4 Molecule)
|
HER-2 positive • HR negative
|
Kadcyla (ado-trastuzumab emtansine) • Jingzhuda (entinostat) • bintrafusp alfa (M7824) • BN-Brachyury
Share via
